Shopping Cart
- Remove All
- Your shopping cart is currently empty
C188-9 (TTI-101) is a Stat3 inhibitor with an IC50 of 4-7 μM.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $38 | In Stock | |
2 mg | $54 | In Stock | |
5 mg | $89 | In Stock | |
10 mg | $125 | In Stock | |
25 mg | $263 | In Stock | |
50 mg | $418 | In Stock | |
100 mg | $625 | In Stock | |
500 mg | $1,330 | Backorder | |
1 mL x 10 mM (in DMSO) | $97 | In Stock |
Description | C188-9 (TTI-101) is a Stat3 inhibitor with an IC50 of 4-7 μM. |
Targets&IC50 | STAT3:4-7 μM |
In vitro | For apoptosis studies, AML cell lines and primary samples are treated for 24 hours with C188-9, then apoptotic cells are quantified by FACS analysis for annexin V-labeled cells. The EC50s for apoptosis induction are quite variable, ranging from 6 μM to over 50 μM |
In vivo | In an analysis of approximately 13,528 discernible genes, C188 influences the expression of 37 gene transcripts (17 downregulated and 20 upregulated, false discovery rate (fdr)<0.01, fold change≥1.5), including 7 known targets of STAT3. Conversely, C188-9 exhibits a broader impact, modifying the expression of 384 genes related to oncogenesis (95 down- and 289 up-regulated), 76 of which are regulated by STAT3 (38 down-regulated and 38 up-regulated). Notably, C188-9 treatment downregulates 24 out of 38 genes (63%) previously identified as upregulated by STAT3. Furthermore, C188-9 downregulates an additional 10 genes (fdr <0.01, fold change≥1.5) known to be upregulated by STAT1, suggesting that 83.3% (40 out of 48) of the genes downregulated by C188-9 are positively regulated by STAT1. This includes sixteen genes co-regulated by both STAT3 and STAT1. The findings suggest that C188-9's modulation of gene transcript levels in head and neck squamous cell carcinoma (HNSCC) tumors may be attributed to its dual influence on STAT3 and STAT1 pathways. |
Alias | TTI-101 |
Molecular Weight | 471.52 |
Formula | C27H21NO5S |
Cas No. | 432001-19-9 |
Smiles | COc1ccc(cc1)S(=O)(=O)Nc1cc(c(O)c2ccccc12)-c1c(O)ccc2ccccc12 |
Relative Density. | 1.416 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 60 mg/mL (127.25 mM), Sonication is recommended. ![]() | |||||||||||||||||||||||||||||||||||
In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 6 mg/mL (12.72 mM), Solution. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.![]() | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.